ストックスクリーナーアプリを入手
0.7063
11.66%
-0.0932
アフターアワーズ：
.69
-0.0163
-2.31%
Ocugen Inc (OCGN) 最新ニュース
Ocugen Advances OCU200 Clinical Trial Amid Promising Safety Results - MSN
Stock Quote & Chart - Ocugen
Ocugen receives DSMB approval to continue dosing in Phase I trial of OCU200 - Yahoo
Ocugen’s OCU200 advances to next trial phase with safety approval By Investing.com - Investing.com Australia
ROSEN, A LEADING LAW FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important August 17 Deadline in Securities Class Action – OCGN - Business Wire
OCGN stock touches 52-week low at $0.52 amid market challenges By Investing.com - Investing.com South Africa
OCGN stock touches 52-week low at $0.52 amid market challenges - Investing.com India
Ocugen Advances OCU200 Trial After Safety Board Review -March 18, 2025 at 08:31 am EDT - Marketscreener.com
Ocugen says DSMB approves dosing Cohort 2 in OCU200 clinical trial - TipRanks
Ocugen’s OCU200 advances to next trial phase with safety approval - Investing.com India
Ocugen Announces Approval to Continue Dosing in Phase 1 Trial of OCU200 Following Favorable Safety Review - Nasdaq
Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema - Ocugen
Data and Safety Monitoring Board Reviews Cohort 1 Safety - GlobeNewswire
Breakthrough in Sight? Ocugen’s OCU200 Targets Vision Loss for Millions in New Clinical Trial - MSN
Ocugen Inc. Navigates Uncertainty Amid Potential Shifts in U.S. Fiscal and Tax Policies - MSN
SBI Securities Co. Ltd. Makes New $40,000 Investment in Ocugen, Inc. (NASDAQ:OCGN) - Defense World
Ocugen, Inc. (NASDAQ:OCGN) Shares Acquired by Rhumbline Advisers - Defense World
Equities Analysts Offer Predictions for Ocugen Q1 Earnings - Defense World
FY2029 Earnings Estimate for Ocugen Issued By HC Wainwright - Defense World
Ocugen’s (OCGN) “Buy” Rating Reiterated at HC Wainwright - Defense World
Ocugen Secures ATMP Classification for Gene Therapies Targeting Vision Loss - MSN
Ocugen Stock Lifts Retail Investor Confidence As Q4 Revenue Crushes Estimates - MSN
Ocugen’s Strategic Advancements and Financial Stability Justify Buy Rating - TipRanks
Ocugen Reports 2024 Financial Results and Advances Gene Therapy Programs - MSN
Attention Long-Term Shareholders of Driven Brands Holdings, - GlobeNewswire
Attention Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); MGP Ingredients, Inc. (NASDAQ: MGPI); and Ocugen, Inc. (NASDAQ: OCGN): Grabar Law Office Investigates Claims on Your Behalf - GlobeNewswire Inc.
Chardan Capital Adjusts Ocugen Price Target to $7 From $6, Maintains Buy Rating -March 06, 2025 at 08:15 am EST - Marketscreener.com
Ocugen, Inc. (NASDAQ:OCGN) Q4 2024 Earnings Call Transcript - Insider Monkey
Ocugen’s Strategic BLA Submissions and Financial Position Support Buy Rating - TipRanks
Beyond The Numbers: 5 Analysts Discuss Ocugen Stock - Benzinga
Y Intercept Hong Kong Ltd Makes New Investment in Ocugen, Inc. (NASDAQ:OCGN) - Defense World
Ocugen: Q4 Earnings Snapshot - Midland Daily News
Ocugen Inc (OCGN) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs - Yahoo Finance
Ocugen Reports Progress in Gene Therapy Trials - TipRanks
Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
Ocugen Inc Earnings Call: Strategic Gains Amid Financial Challenges - TipRanks
Around the Helix: Cell and Gene Therapy Company Updates – March 5, 2025 - CGTLive™
Ocugen Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Ocugen (OCGN) Q4 2024 Earnings Call Transcript - Yahoo
Ocugen’s Geographic Atrophy and Stargardt Gene Therapies Garner Positive ATMP Opinions from EMA - CGTLive™
Earnings call transcript: Ocugen Q4 2024 beats earnings forecast By Investing.com - Investing.com UK
Ocugen to Announce Q4 and Full-Year 2024 Results with Live Webcast on March 5, 2025 - MSN
Ocugen, Inc. SEC 10-K Report - TradingView
Earnings call transcript: Ocugen Q4 2024 beats earnings forecast - Investing.com
1.05%
1.79%
大文字化:
|
ボリューム (24 時間):